

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues were raised during the scoping process. However, one consultee noted that *“as MPM is a preventable, occupation-related disease caused by asbestos exposure, ... MPM incidence rates vary across England, with higher rates in areas of heavy industry (e.g., the North East and Southern England). Also, as MPM is a rare cancer, patients may be referred for treatment in the NHS in a limited number of specialist quaternary centres, which may require patients to travel long distances from their home if they live in a rural setting. As patients with MPM are often old and diagnosed at a late stage, they can be too frail to travel for treatment.”*

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal. Issues related to implementation will be considered by the committee during the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Nicole Elliott

Date: 23/09/2020